
Global Cord Blood Corporation CO
Annual report 2022
added 08-16-2022
Global Cord Blood Corporation Accounts Receivables 2011-2026 | CO
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables Global Cord Blood Corporation
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 416 M | 348 M | 264 M | 202 M | 210 M | 248 M | 290 M | 315 M | 321 M | 322 M | 79 M | - |
All numbers in CNY currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 416 M | 79 M | 274 M |
Quarterly Accounts Receivables Global Cord Blood Corporation
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 416 M | - | 145 M | - | 348 M | - | 122 M | - | 264 M | - | 97.1 M | - | 202 M | - | 105 M | - | 210 M | - | 112 M | - | 248 M | - | 119 M | - | 290 M | - | 125 M | - | 315 M | - | 110 M | - | 321 M | - | 80.6 M | 75.4 M | 322 M | - | 78.6 M | 80.3 M | 333 M | 79.9 M | 81.1 M | - | 77.4 M |
All numbers in CNY currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 416 M | 75.4 M | 183 M |
Accounts Receivables of other stocks in the Diagnostics research industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Agilent Technologies
A
|
1.17 B | $ 115.48 | 0.82 % | $ 35.1 B | ||
|
Burning Rock Biotech Limited
BNR
|
88.2 M | $ 16.2 | -0.61 % | $ 175 M | ||
|
Biodesix
BDSX
|
8.6 M | $ 15.07 | 2.1 % | $ 1.95 B | ||
|
Aspira Women's Health
AWH
|
1.21 M | - | -6.19 % | $ 10.5 M | ||
|
Co-Diagnostics
CODX
|
190 K | $ 4.4 | 101.83 % | $ 5.85 M | ||
|
Castle Biosciences
CSTL
|
51.2 M | $ 24.84 | -0.84 % | $ 690 M | ||
|
DarioHealth Corp.
DRIO
|
2.14 M | $ 8.4 | 3.7 % | $ 33.5 M | ||
|
BioNano Genomics
BNGO
|
5.2 M | $ 1.2 | 0.84 % | $ 6.53 M | ||
|
Akumin
AKU
|
114 M | - | -17.87 % | $ 25.9 M | ||
|
Charles River Laboratories International
CRL
|
709 M | $ 173.89 | -0.58 % | $ 8.62 B | ||
|
Accelerate Diagnostics
AXDX
|
2.42 M | - | -61.36 % | $ 2.46 M | ||
|
DexCom
DXCM
|
1.22 B | $ 62.22 | -0.24 % | $ 24.3 B | ||
|
Fulgent Genetics
FLGT
|
69 M | $ 16.82 | 2.31 % | $ 509 M | ||
|
Biomerica
BMRA
|
731 K | $ 2.17 | -0.91 % | $ 4.98 M | ||
|
Exact Sciences Corporation
EXAS
|
299 M | - | - | $ 19.8 B | ||
|
DermTech
DMTK
|
2.58 M | - | -11.32 % | $ 2.94 M | ||
|
Quest Diagnostics Incorporated
DGX
|
1.41 B | $ 198.02 | 0.17 % | $ 22 B | ||
|
Guardant Health
GH
|
138 M | $ 93.83 | 2.94 % | $ 11.8 B | ||
|
Enzo Biochem
ENZ
|
3.99 M | - | -8.98 % | $ 14.8 K | ||
|
Lantheus Holdings
LNTH
|
359 M | $ 76.1 | 0.53 % | $ 5.14 B | ||
|
Biocept
BIOC
|
2.15 M | - | -13.05 % | $ 7.29 M | ||
|
Medpace Holdings
MEDP
|
402 M | $ 498.34 | 1.81 % | $ 14.4 B | ||
|
Heska Corporation
HSKA
|
29.5 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
1.42 M | - | -20.0 % | $ 1.06 M | ||
|
Interpace Biosciences
IDXG
|
5.65 M | $ 1.96 | 5.82 % | $ 8.67 M | ||
|
Mettler-Toledo International
MTD
|
778 M | $ 1 259.94 | -1.11 % | $ 26 B | ||
|
ICON Public Limited Company
ICLR
|
1.34 B | $ 114.19 | 2.49 % | $ 9.42 B | ||
|
IDEXX Laboratories
IDXX
|
552 M | $ 569.55 | 0.87 % | $ 45.8 B | ||
|
Neogen Corporation
NEOG
|
153 M | $ 9.41 | 0.21 % | $ 2.04 B | ||
|
Illumina
ILMN
|
735 M | $ 127.38 | 0.59 % | $ 20.3 B | ||
|
IQVIA Holdings
IQV
|
3.4 B | $ 173.26 | 0.5 % | $ 29.8 B | ||
|
Pacific Biosciences of California
PACB
|
35.4 M | $ 1.34 | -0.74 % | $ 402 M | ||
|
QIAGEN N.V.
QGEN
|
381 M | - | - | $ 10.6 B | ||
|
Motus GI Holdings
MOTS
|
76 K | - | -34.28 % | $ 263 K | ||
|
Chembio Diagnostics
CEMI
|
6.54 M | - | 0.22 % | $ 16.8 M | ||
|
Laboratory Corporation of America Holdings
LH
|
2.1 B | $ 273.72 | 0.36 % | $ 22.8 B | ||
|
Myriad Genetics
MYGN
|
115 M | $ 4.75 | 3.49 % | $ 440 M | ||
|
Sotera Health Company
SHC
|
139 M | $ 14.96 | 0.61 % | $ 4.25 B | ||
|
NeoGenomics
NEO
|
159 M | $ 8.0 | 3.23 % | $ 1.02 B | ||
|
National Research Corporation
NRC
|
11.1 M | $ 17.16 | -1.04 % | $ 384 M |